Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hellmann, MD
  • Cho, BC
  • Juergens, Rosalyn
  • Cheng, Y
  • De Castro, G
  • Erman, M
  • Bauman, JR
  • Takahashi, T
  • Schwarzenberger, P
  • Zhang, P
  • Pietanza, MC
  • Yang, JC

publication date

  • October 2021